$COSM

Cosmos Health (NASDAQ:COSM) said it expanded its Sky Premium Life distribution partnership with Pharma Cell in Albania. Average monthly orders already exceed 4,500 units, and annualized orders are projected to top 54,000. The products are distributed nationwide via Pharma Cell’s network and recommended by doctors and healthcare professionals.

Cosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 274,000 shares in the open market at an average price of about $0.2554 per share. Total buybacks under its up to $5 million program reached 5,112,000 shares for about $1.11 million. The program expires Dec. 31, 2026.

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. cosm_8k.htm 0001474167 false --12-31 0001474167 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act o

Cosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 250,000 shares in the open market at an average price of about $0.2782 per share. Total repurchases under its up to $5 million program reached 4,838,000 shares for about $1.04 million. The program expires Dec. 31, 2026 and may continue subject to conditions.

Cosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 100,000 shares in the open market at an average price of about $0.2928. Total repurchases under its up to $5 million program reached 4,588,000 shares for about $970,000. The company plans to continue repurchases through Dec. 31, 2026.

Cosmos Health Inc. (NASDAQ:COSM) said it repurchased an additional 133,000 shares in the open market at an average price of about $0.298 per share. Total buybacks under its $5 million program reached about 4.488 million shares for about $941,000. The program expires Dec. 31, 2026 and may be renewed.

Cosmos Health Inc. (NASDAQ:COSM) said it repurchased 215,000 shares in the open market at an average price of about $0.325 per share. Total buybacks under its program reached 4,355,000 shares for about $901,000, with up to $5 million authorized. The company plans to continue repurchases through Dec. 31, 2026.

Cosmos Health (NASDAQ:COSM) said it signed a five-year agreement with Libytec to commercialize DIABIT-IS X (sitagliptin) in Greece. Cosmos, via Cana, will supply the drug, while Libytec will distribute and promote it to physicians and pharmacies. The company expects the deal to support revenue and cash-flow visibility, citing Greece’s national reimbursement system.

Cosmos Health Inc. (NASDAQ:COSM) said it launched a subscription purchasing model in the US for its NOOR Collagen product. The company reported early results including a repeat purchase rate above 60% and margins above 50%. Cosmos plans to expand the subscription model to more consumer health products globally and expects more metrics as it matures.

Cosmos Health Inc. (NASDAQ:COSM) said it launched a subscription purchasing model in the US for its NOOR Collagen brand. The company reported early results with repeat purchase rates above 60% and margins above 50%. Cosmos plans to expand the model to other consumer health products globally and provide more metrics as it matures.